**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 4319**

**Columns: REVIEW**

Endotherapy in chronic pancreatitis

Tandan M *et al*. Endoscopic therapy in chronic pancreatitis

Manu Tandan, D Nageshwar Reddy

**Manu Tandan, D Nageshwar Reddy,** Department of Medical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad 500082, India

**Author contributions:** Tandan M conceptualized the article, wrote the article and original work in the management of pancreatic calculi; Reddy DNprovided the inputs, original work in management of pancreatic leaks and pancreatic calculi.

**Correspondence to: D Nageshwar Reddy,** **MD, DM, DSc, FAMS, FRCP, FASGE, FACG, MWGO,** Department of Medical Gastroenterology, Asian Institute of Gastroenterology, 6-3-661, Somajiguda, Hyderabad 500082, India. aigindia@yahoo.co.in

**Telephone:** +91-40-23378888 **Fax:** +91-40-23324255

**Received:** June 26, 2013 **Revised:** August 13, 2013

**Accepted:** August 20, 2013

**Published online:**

**ABSTRACT**

Chronic pancreatitis (CP) is a progressive disease with irreversible changes in the pancreas. Patients commonly present with pain and with exocrine or endocrine insufficiency. All therapeutic efforts in CP are directed towards relief of pain as well as the management of associated complications. Endoscopic therapy offers many advantages in patients with CP who present with ductal calculi, strictures, ductal leaks, pseudocyst or associated biliary strictures. Endotherapy offers a high rate of success with low morbidity in properly selected patients. The procedure can be repeated and failed endotherapy is not a hindrance to subsequent surgery. Endoscopic pancreatic sphincterotomy is helpful in patient of CP with minimal ductal changes while minor papilla sphincterotomy provides relief in patient of pancreas divisum and chronic pancreatitis. ESWL is the standard of care in patients with large pancreatic ductal calculi. Long term follow up has shown pain relief in over 60% of patients. For ductal leaks, transpapillary stent placed across the disruption provides relief in over 90% patients. Pancreatic ductal strictures are managed by single large bore stents. Multiple stents are placed for refractory strictures. CP associated benign biliary strictures (BBS) are best treated with multiple plastic stents, as the response to single plastic stent is poor. Covered Self Expanding Metal Stents are increasingly being used in the management of BBS though further long term studies are needed. Pseudocysts are best drained endoscopically with a success rate of 80%-95% at most centers. Endosonography (EUS) has added to the therapeutic armamatorium in the management of patients with CP. Drainage of pseudcyst, cannulation of inaccessible pancreatic ducts as well as celiac ganglion block in patients with intractable pain are all performed using EUS. Endotherapy should be offered as the first line of therapy in properly selected patients of CP who have failed to respond to medical therapy and require intervention.

© 2013 Baishideng. All rights reserved.

**Key words:** Chronic pancreatitis; Endoscopic retrograde cholangiopancreatography; Pancreatic sphincterotomy; Extracorporeal shockwave lithotripsy; Endosonography

**Core tip:** Chronic pancreatitis is a challenge to the therapeutic endoscopist. A patient of chronic pancreatitis can present with ductal calculi, leaks, pseudocysts, strictures, pancreatic malignancy or a biliary obstruction. Endoscopic therapy offers a high rate of success in properly selected patients. It offers many advantages over surgery, which for long was considered the gold standard in the treatment of chronic pancreatitis. This chapter deals with the management of chronic pancreatitis associated strictures, calculi, leaks and pseudocysts. The role of endosonography in management of pseudocyst, cannulation of inaccessible ducts and pain relief has also been discussed.

Tandan M, Reddy DN. Endotherapy in chronic pancreatitis.

**Available from: URL:**

**DOI:**

**INTRODUCTION**

Chronic pancreatitis (CP) is a disease of varied etiology and characterized by progressive and irreversible damage to the pancreas with resultant loss of both endocrine and exocrine functions. Alcohol, smoking, genetic factors and metabolic disorders are common etiological causes[1]. In our country the non alcoholic type of CP is more prevalent[2,3]. Irrespective of the etiology, majority of the patients of the CP present with pain as the dominant symptom.

As the disease is irreversible almost all therapeutic efforts are directed towards control of pain and management of complications associated with CP. For the therapeutic endoscopist, CP is a challenge as patients can present with ductal strictures, calculi, ductal disruption, pseudocyst, biliary strictures, duodenal narrowing or a pancreatic malignancy. Endotherapy is performed in patients with CP who are unlikely to respond or have failed medical therapy as well as to manage the above mentioned complications. Surgery has often been considered the best therapeutic option for patients with CP[4]. However with advances in technology and techniques, endotherapy is offered as first line of management in many patients with CP. Endotherapy offers many distinct advantages over surgery. It has a high success rate and low morbidity in properly selected patients. The procedure can be repeated with no extra risk unlike the morbidity and difficulty associated with repeat surgery. The results are comparable to surgery and failed endotherapy does not hinder subsequent surgery[5-8] . Endoscopic approach can also predict the response to surgical therapy[9]. The endoscopic techniques used are endoscopic retrograde cholangiopancreatography (ERCP) and endosonography (EUS). Extracorporeal shockwave lithotripsy (ESWL) is a part of the endoscopic armamentarium. Advances in EUS have improved therapeutic options including pseudocyst drainage as well as cannulation of inaccessible main pancreatic duct (MPD).

In this review, we will discuss the role of endotherapy in diagnosis and management of CP related pancreatic ductal stricutres, stones, CBD strictures and pseudocyst.

**ROLE OF ENDOSCOPY IN THE DIAGNOSIS OF CP**

ERCP was earlier used both for diagnosis and management of patients with CP. It has sensitivity of 73%-94% and specificity of 90%-100% in visualizing duct related changes in CP[10]. The emergence of Magnetic resonance cholangiopancreatography (MRCP) with secretin stimulation as well as EUS has minimized the role of ERCP in diagnosing CP. EUS is a better diagnostic modality especially in early and less advanced CP as it identifies both ductal and parenchymal changes[11]. EUS has sensitivity of close to 100% as compared to 80% with ERCP in patients with early CP[12]. MRCP being non invasive offers a better alternative to ERCP for visualizing ductal changes.

**CP WITH MINIMAL DUCTAL CHANGES**

Painful CP can occasionally present with minimal or no ductal change in absence of ductal strictures or stones. This is classified as type I CP according to Cremer classification or mild CP of Cambridge classification[13,14]. Endoscopic pancreatic sphincterotomy (EPS) is a documented mode of therapy and offers symptomatic relief in some of these patients. Both the standard pull type and the needle knife sphincterotomy over a stent can be performed. A 64% relief in pain on follow up of 6.5years has been reportedfollowing EPS[15]. High success rates of 98% and low complication of around 4% have been reported on retrospective analysis[16]. Randomized studies have shown a higher incidence of pancreatitis in high risk patients following pull type sphincterotomy as compared to needle knife technique[17]. Most workers report an incidence of around 12% for post EPS pancreatitis. Placement of nasopancreatic tube (NPT) or pancreatic stent can reduce this incidence significantly[18]. Re-stenosis is reported in around 14% of patients on long term follow up[19]. It is believed that restenosis is less common following the longer incision with the pull type as compared to needle knife technique[20]. The presence of periductal fibrosis seen in patients with CP may lower the incidence of post procedure pancreatitis. An additional biliary spincterotomy is only indicated in the following conditions[21]. (1) Presence of cholangitis; (2) Common bile duct (CBD) > 12 mm diameter; (3) Serum alkaline phosphates > 2 times upper limit of normal; and (4) Difficult access to MPD

***Minor papilla sphincterotomy***

Minor papilla sphincterotomy (MiES) was first performed by Peter Cotton in 1978[22]. It is indicated in those patients of CP with minimal ductal change who have a pancreas divisum or a dominant dorsal duct. Both the pull type and needle knife technique can be used. The evidence of any definite benefit from MiES is debatable as studies include small number of heterogeneous patients and are not conclusive. Significant pain relief on a two year follow up has been reported following MiES and stenting of patients with CP[23]. Relief of pain is also seen in 41% of patients with CP following MiES as compared to 77% with acute recurrent pancreatitis or 33% of patients with CP with no pain[24]. Post ERCP pancreatitis has been reported upto 15% of patients[25] and restenosis was seen in 20%-24% on a 6 year follow up[26].

**ENDOSCOPIC MANAGEMENT OF PANCREATIC DUCTAL STRICTURES**

Strictures of MPD are frequently seen as a consequence of CP and could be due to inflammation or fibrosis. In our experience of 1000 patients who underwent ESWL, the incidence of strictures was 18%[2]. MPD strictures are defined as a high grade narrowing of MPD with one of the following[9,27]. (1) MPD dilatation > 6 mm beyond the stricture; (2) Failure of contrast to flow along side the stricture or 6Fr naso-pancreatic tube (NPT); and (3) Presence of pain during continuous perfusion of the NPT with normal saline for 24 h.

Endotherapy is ideal for single strictures in the head while isolated strictures in the tail or multiple strictures with chain of lake appearance are not amenable to endotherapy[9]. Prior to stent placement tight strictures need to be dilated with Teflon bougies, Sohendra stent retriever or a balloon dilator[9,27]. Large bore stents 7-10 Fr should be deployed as they have longer patency[,27]. Delhaye *et al*[27] followed a protocol where a single stent was placed across a stricture and exchanged every 6 mo or when the patient was symptomatic. Stents were placed for 24 mo. Patients were re stented if symptoms recurred. Surgery was considered if patients responded to stent placement but needed frequent or repeated stenting. Cumulative data from several workers revealed pain relief between 70%-94% for single pancreatic stent on follow up of 14-69 mo[9]. Recurrence of strictures was reported in 38% patients on follow up of 2 years[28]. The concept of multiple plastic stent for MPD strictures not responding to single stent placement was advocated by Costamagna *et al*[29]. In their study, after removal of single stent, the stricture was dilated and multiple plastic stents 8.5 - 11.5 Fr diameter were placed. A mean of 3 stents were used. The stents were removed 12 mo later. Stricture resolution was seen in 95% and pain relief in 84% on a 38 mo follow up.

Complications with pancreatic stenting can occur. Occlusion was seen with passage of time and migration was present in 10% of patients[30]. Distal migration and impaction on the opposite duodenal wall can cause peforation while proximal migration into the pancreas is a technical challenge for the endoscopist. The possibility of stent induced fibrosis has raised concerns[31]. However with the preexisting fibrosis of MPD there has been no significant clinical impact. The search for an ideal pancreatic stent continues and a new “wing stent” to prevent clogging as well as an “S” shaped stent to prevent migration are undergoing evaluation[32,33]. The use of covered metal stents (CSEMS) for pancreatic strictures is also under evaluation. The initially used CSEMS had the disadvantage of stent migration. Subsequently a new “bumpy stent” has been tried for a MPD strictures in 32 patients[34,35]. The stent had antimigratory properties and its contours adapted to the MPD. These were extracted in at 3 mo and were effective in resolving the MPD strictures. However they were associated with the formation of denovo strictures and further trials are needed to evaluate their long term efficacy and safety.

European Society of Gastrointestinal Endoscopy (ESGE) guidelines state that dominant PD strictures be treated by placing a single 10 Fr stent with stent exchanges planned for 1 year. Multiple plastic stents should be deployed in a stricture which persists after 1 year of single stent placement[36]. Uncovered SEMS should not be placed in MPD. ESGE guidelines also state that temporary placement of fully covered SEMS should only performed in the setting of trials[36].

**ENDOTHERAPY OF PANCREATIC DUCTAL CALCULI**

Pancreatic dutal calculi are a consequence of CP and tend to aggravate or produce pain by obstructing pancreatic ducts and producing upstream hypertension. They can occur in 50% of patients with CP[8]. Stones seen in the tropics and of the non alcoholic type of CP tend to be larger and denser than those seen in the alcoholic variety[37,38]. The large size could also be due to delay in reporting for therapy[2]. Stones > 5 mm in size can usually be extracted with Dormia basket, balloon trawl following EPS. However stones >5mm in size are often impacted and difficult to extract by the standard techniques[2,37,39]. Large calculi need to be fragmented prior to extraction or spontaneous expulsion from the MPD. ESWL is now accepted as the standard of care in the management of large PD calculi not amenable to routine endotherapy[2,36,37,40-45]. ESWL is very effective in fragmenting both radio opaque and radio lucent calculi in the MPD. A meta analysis of 17 studies with a total of 491 patients revealed clearance rate between 37%-100% and good pain relief[46]. Another review of 11 studies with over 1100 patients showed successful stones fragmentation in 89%[47]. Our own single center study of over 1000 patients shows complete clearance in 76% patients and partial clearance in another 17% patients following ESWL and endotherapy for large calculi[2]( Figures 1 and 2).

The following protocol is followed at our center for patients with large PD calculi[2]. Patients with large calculi in the head or body and with pain as the main complaint are subjected to ESWL. Patients with isolated calculi in tail, multiple MPD stricutres, extensive calculi in head, body and tail, associated head mass, pseudocyst and pregnancy are excluded from ESWL. The procedure is performed with a III generation electromagnetic lithotripter with bi-dimensional fluoroscopy and ultrasound targeting facility. (Delta compact–Dornier MedTech Wessling Germany). Epidural anesthesia is preferred in most patients[48]. It is effective and offers many advantages as reported in our study of over 1500 patients. Radio opaque calculi are subjected to ESWL under fluoroscopic guidance. For radiolucent calculi a nasopancreatic tube (NPT) is placed and contrast is passed through this tube to help localize the calculi. The aim of fragmentation is to break the calculi to 3 mm or less to facilitate to their extraction or expulsion[2,49]. An average of 3 sessions is generally required (5000-6000 shocks per session). The protocol is shown in Figure 3. A few studies have advocated use of ESWL alone followed by spontaneous expulsion of fragments[50]. A randomized controlled trial of 55 patients compared results of ESWL and ERCP with ESWL alone. The only difference was higher cost and longer stay in the ESWL and ERCP group[51]. At our center, we prefer to extract the fragments from the MPD by ERCP following the ESWL procedure as fragments tend to be denser and adherent and do not clear spontaneously[2,49].

Short term pain relief following ESWL was seen in 84% of our patients[2] and similar results have been reported by others[39]. Very few long term follow up studies are available. Two-thirds of patients were found to be pain free on long term follow up[8,52]. A recent study showed pain relief in 85%, complete pain relief with no narcotic use in 50% and avoidance of surgery in 84% of 120 patients on long term follow up after ESWL[53]. Our own data on long term follow up is encouraging and over 60% of patients are pain free on follow up of more than 5years[54]. In conclusion, in properly selected group of patients, with large PD calculi ESWL is a useful tool and provides adequate long term pain relief. A few patients also benefit in exocrine and endocrine dysfunction though the numbers are too small to be significant[54]. ESWL is a safe procedure and well tolerated. Minor side effects such as transient pain and bruising of skin at site of shock delivery have been described[2,37,49]. The incidence of pancreatitis is not higher following ESWL.

Other techniques for extraction of large PD calculi include intraductal laser or electro hydraulic lithotripsy through a pancreatoscope or spyscope[55,56]. Experience with these modalities is small and success rates are discordant. These procedures are technically difficult and require non standard equipment. At present, they are only to be considered as second line management after failed ESWL[36].

**CHRONIC PANCREATITIS RELATED BENIGN BILIARY STRICTURES**

CBD strictures occur in 3%-46% of patients with CP[30]. Strictures can be reversible due to inflammation or compression with a pseudocyst. They are irreversible following fibrosis. ESGE guidelines recommend treating CP related benign biliary strictures (BBS) in case of symptoms, secondary biliary cirrhosis, biliary stones, asymptomatic elevation of serum alkaline phosphates > 2-3 times upper limit of normal or raised serum bilirubin persisting for over 1 month[36]. Placement of a single plastic stent in the CBD is associated with poor success rates. Long term results have disappointing and sustained benefit is seen in around 25% of patients on follow up of 46mo[57]. Single plastic stents are associated with poor resolution and higher relapse rate. The presence of pancreatic head calcification is an important factor for failure of this therapy[58]. Placement of multiple plastic stents in CP related BBS is technically successful in over 95% of patients and offers the best results. Complete therapy requires approximately four ERCP procedures and stents exchanges performed every 3 mo for 1 year. Single stents provided a relief in 31% of 350 patients as compared to 62% in 50 patients who received multiple stents[36]. Catalano *et al*[59] performed a non randomized study comparing single and multiple plastic stents in CP related BBS. Clinically success was reported in 92% with multiple stents as compared to 24% with single stents. Uncovered SEMS for BBS are not advocated and partially or fully covered SEMS have been used with a success rate of 50%-80% on follow up for 22-28 mo[60,61]. A recently conducted multi center trial using fully covered SEMS (FCSEMS) in BBS included 127 patients of CP. It concluded that FCSEMS may be useful for treatment of BBS particularly in patients of CP[62]. There has been no head to head study comparing the single or multiple plastic stents and metal stents in BBS due to CP and surgery. The choice and option of surgery depend up on patient preference, expertise at the treating center as well as the presence of co morbidities such as cirrhosis or collaterals.

**PANCREATIC DUCTAL LEAKS**

Leaks from the MPD or side branches can occur following blow out of the ducts due to obstruction by stone or strictures. PD leak is defined as extravasation of contrast material from the ductal system at ERCP[63]. Disruption could be partial or complete and leads to fluid collection, pseudocyst, ascites, pleural effusion and external or internal fistulas[9,27]. Placement of transpapillary stents offers the best treatment in patients with PD disruption as it converts the high pressure ductal system into a low pressure one with preferential flow across the stents[27]. Resolution of leak was seen in 92% of patients if the stent bridged the disruption, 50% when placed proximal to the disruption and 44% were a short transpapillary stent was placed[63](see Figure 4). In patients with complete transection where stenting is not feasible a multi disciplinary approach with a help of interventional radiologist or the surgeon may be required.

**ENDOSCOPY OF PSEUDOCYST**

Pancreatic pseudocyst (PPC) in CP is the result of disruption of the MPD or it’s side branches occurs in 20%-40% of patients[64]. Disruption generally follows obstruction by stone or stricture. Treatment is indicated for symptomatic PPC or those which increase in size. Symptoms result due to compression of adjacent structures or due to infection. It has also been suggested that prophylactic treatment be performed in certain specific situations to prevent complications. These include pancreatoplural fistula, cysts > 5mm lasting for over 6 wk, compression of major vessels or presence of large pancreatic stones in MPD[65]. There is generally a low rate of spontaneous resolution of PPC in patients with CP though small asymptomatic cysts can be followed up[66]. Drainage of pseudocyst can be transmural (Transgastric or transduodenal) or transpapillary. Transmural drainage is ideal for PPC which bulge into the lumen of stomach or duodenum. Transduodenal drainage offers best success when compared to transgastric drainage[67]. This is because cystoduodenal fistulas tend to remain patent longer than cystogastric fistulas. Placement of one or more pig tailed stents is better when compared to straight stents. Straight stents are associated with higher rate of bleed (around 7%) as well as migration[68]. Stent should be left in place for longer duration as their removal with-in 2 mo is associated with higher incidence of PPC recurrence[36]. Pseudoaneurysm can complicate management of PPC because of the associated haemorrhage and a consequent high mortality[69]. Delhaye *et al*[27] recommend prophylactic embolization of pseudoaneurysm prior to drainage of an adjacent PPC.

Transpapillary drainage is reserved for small cysts (< 6 cm size) and those in communication with the MPD. The role of EUS guided drainage for non bulging PPC will be discussed in next section. Comparison of EUS guided drainage with surgery in an RCT revealed that endoscopic drainage was significantly better than surgery in terms of cost and length of stay over a 3 month follow up[70]. Complications include bleed, infection and leak of around 4% each with a mortality of 0.5%[71]. Infection is more likely with transpapillary drainage and leak is more likely with transmural drainage. Routine antibiotic administration is recommended for drainage of PPC[72]. With a success rate of 80%-95% at most centers, recurrence rate of 10-20% and results comparative or better than surgery endoscopy is the preferred first line of management in patients of PPC in the background of CP[27,36].

**ENDOSONOGRAPHY IN CP**

Endosonography (EUS) is an excellent diagnostic modality especially in patients with early CP. It also has definite therapeutic role in the following situations and these are discussed briefly.

***PPC drainage***

EUS is ideal for drainage of non bulging PPC and cysts as far as 4cm from the stomach or duodenal wall have been drained[73]. 44%-53% of PPC’s belong to this category. In the presence of collaterals the site of drainage is better identified with EUS, thus making the procedure safer. Complication rate is however similar when PPC’s are drained with or with out EUS guidance[74]. A recent randomized trial comparing EUS guided and surgical cystogastrostomy for pseudocyst revealed shorter hospital stay, lower cost and better physical and mental health in the endoscopy group. None in the endoscopy group had pseudocyst recurrence and therapy was successful in all the patients[75].

***EUS guided access of MPD***

EUS guided access or drainage is indicated following failed conventional drainage of MPD. It can be via the stomach (Pancreatogastric) or duodenum (pancreatobulbar). The duodenal route is preferred because better stability of the EUS scope[9]. A guidewire can be passed into the duodenum for a rendezvous procedure or transmural drainage can be performed. Success rate of 77%-92% have been reported[76,77]. Complications include pain, bleed, perforation and haemotoma. And morbidity of 0%-44% has been reported[76-78]. EUS guided access of the MPD is a technically challenging procedure and should always be performed by experts and under radiological guidance[9].

***EUS guided celiac block***

Patients who have failed to respond to intensive medical or endoscopic therapy and are not candidates suitable for surgery can be provided relief from pain by EUS guided celiac block. A combination of corticosteriods (Trimcinolone) and anesthetic agent (bupivacaine) is injected in and around the celiac plexus under EUS guidance. Recent meta analysis has reported pain relief in 50%-55% of patients though the pain relief is transient[79,80]. Patients who are younger than 45years or have previous pancreatic surgery are less likely to benefit[81]. EUS guided celiac block is shown to be superior to fluoroscopy guided celiac block for pain relief and pain preference in our study[82]. EUS guided nerve block can produce diarrhea, hypertension due to sympathetic blockade and unopposed parasympathetic activity[11,80].

In conclusion, management of CP is a multi disciplinary task involving the physician, endoscopist, interventional radiologist and surgeon. Their roles are complementary to each other. As mentioned earlier endotherapy is effective, less invasive than surgery, offers good results and associated with low morbidity and mortality. It can be repeated and does not interfere with any subsequent surgical procedure. It is therefore advisable to offer endotherapy as the first line treatment in properly selected patients with CP.

**REFERENCES**

1 **Lankisch PG**, Banks PA, eds. Pancreatitis, New York, Berlin: Springer-Verlag, 1998; 199. doi: 10.1007/978-3-642-80320-8\_13

2 **Tandan M**, Reddy DN, Santosh D, Vinod K, Ramchandani M, Rajesh G, Rama K, Lakhtakia S, Banerjee R, Pratap N, Venkat Rao G. Extracorporeal shock wave lithotripsy and endotherapy for pancreatic calculi-a large single center experience. *Indian J Gastroenterol* 2010; **29**: 143-148 [PMID: 20717860 DOI: 10.1007/s12664-010-0035-y]

3 **Balakrishnan V**, Unnikrishnan AG, Thomas V, Choudhuri G, Veeraraju P, Singh SP, Garg P, Pai CG, Devi RN, Bhasin D, Jayanthi V, Premalatha N, Chacko A, Kar P, Rai RR, Rajan R, Subhalal N, Mehta R, Mishra SP, Dwivedi M, Vinayakumar KR, Jain AK, Biswas K, Mathai S, Varghese J, Ramesh H, Alexander T, Philip J, Raj VV, Vinodkumar A, Mukevar S, Sawant P, Nair P, Kumar H, Sudhindran S, Dhar P, Sudheer OV, Sundaram KR, Tantri BV, Singh D, Nath TR. Chronic pancreatitis. A prospective nationwide study of 1,086 subjects from India. *JOP* 2008; **9**: 593-600 [PMID: 18762690]

4 **Cahen DL**, Gouma DJ, Nio Y, Rauws EA, Boermeester MA, Busch OR, Stoker J, Laméris JS, Dijkgraaf MG, Huibregtse K, Bruno MJ. Endoscopic versus surgical drainage of the pancreatic duct in chronic pancreatitis. *N Engl J Med* 2007; **356**: 676-684 [PMID: 17301298 DOI: 10.1056/NEJMoa060610]

5 **Bradley EL**. Long term results of pancreaticojejunostomy in patients with chronic pancreatitis. American Journal of Surgery 1987; **153:** 207–13. doi: 10.1016/0002-9610(87)90816-6

6 **Cremer M**, Devière J, Delhaye M, Baize M, Vandermeeren A. Stenting in severe chronic pancreatitis: results of medium-term follow-up in seventy-six patients. *Endoscopy* 1991; **23**: 171-176 [PMID: 1860448 DOI: 10.1055/s-2007-1010649]

7 **Farnbacher MJ**, Schoen C, Rabenstein T, Benninger J, Hahn EG, Schneider HT. Pancreatic duct stones in chronic pancreatitis: criteria for treatment intensity and success. *Gastrointest Endosc* 2002; **56**: 501-506 [PMID: 12297764 DOI: 10.1016/S0016-5107(02)70433-1]

8 **Rösch T**, Daniel S, Scholz M, Huibregtse K, Smits M, Schneider T, Ell C, Haber G, Riemann JF, Jakobs R, Hintze R, Adler A, Neuhaus H, Zavoral M, Zavada F, Schusdziarra V, Soehendra N. Endoscopic treatment of chronic pancreatitis: a multicenter study of 1000 patients with long-term follow-up. *Endoscopy* 2002; **34**: 765-771 [PMID: 12244496 DOI: 10.1055/s-2002-34256]

9 **Tringali A**, Boskoski I, Costamagna G. The role of endoscopy in the therapy of chronic pancreatitis. *Best Pract Res Clin Gastroenterol* 2008; **22**: 145-165 [PMID: 18206819 DOI: 10.1016/j.bpg.2007.10.021]

10 **Enríquez WK**. [Diagnostic and therapeutic endoscopy of pancreas and biliary tract]. *Rev Gastroenterol Mex* 2006; **71** Suppl 1: 36-38 [PMID: 17037767]

11 **Attasaranya S**, Abdel Aziz AM, Lehman GA. Endoscopic management of acute and chronic pancreatitis. *Surg Clin North Am* 2007; **87**: 1379-402, viii [PMID: 18053837 DOI: 10.1016/j.suc.2007.08.006]

12 **Kahl S**, Glasbrenner B, Leodolter A, Pross M, Schulz HU, Malfertheiner P. EUS in the diagnosis of early chronic pancreatitis: a prospective follow-up study. *Gastrointest Endosc* 2002; **55**: 507-511 [PMID: 11923762 DOI: 10.1067/mge.2002.122610]

13 **Cremer M**, Toussaint J, Hermanus A, Deltenre M, De Tceuf J, Engelholm L. [Primary chronic pancreatitis. A classification based on endoscopic pancreatography (author's transl)]. *Acta Gastroenterol Belg* 1976; **39**: 522-546 [PMID: 1023728]

14 **Sarner M**, Cotton PB. Classification of pancreatitis. *Gut* 1984; **25**: 756-759 [PMID: 6735257 DOI: 10.1136/gut.25.7.756]

15 **Gabbrielli A**, Mutignani M, Pandolfi M, Perri V, Costamagna G. Endotherapy of early onset idiopathic chronic pancreatitis: results with long-term follow-up. *Gastrointest Endosc* 2002; **55**: 488-493 [PMID: 11923759 DOI: 10.1067/mge.2002.122651]

16 **Ell C**, Rabenstein T, Schneider HT, Ruppert T, Nicklas M, Bulling D. Safety and efficacy of pancreatic sphincterotomy in chronic pancreatitis. *Gastrointest Endosc* 1998; **48**: 244-249 [PMID: 9744598 DOI: 10.1016/S0016-5107(98)70185-3]

17 **Varadarajulu S**, Wilcox CM. Randomized trial comparing needle-knife and pull-sphincterotome techniques for pancreatic sphincterotomy in high-risk patients. *Gastrointest Endosc* 2006; **64**: 716-722 [PMID: 17055863 DOI: 10.1016/j.gie.2006.02.058]

18 **Hookey LC**, RioTinto R, Delhaye M, Baize M, Le Moine O, Devière J. Risk factors for pancreatitis after pancreatic sphincterotomy: a review of 572 cases. *Endoscopy* 2006; **38**: 670-676 [PMID: 16810591 DOI: 10.1055/s-2006-925447]

19 **Kozarek RA**, Ball TJ, Patterson DJ, Brandabur JJ, Traverso LW, Raltz S. Endoscopic pancreatic duct sphincterotomy: indications, technique, and analysis of results. *Gastrointest Endosc* 1994; **40**: 592-598 [PMID: 7988825 DOI: 10.1016/S0016-5107(94)70260-8]

20 **Siegel JH**, Cohen SA. Pull or push pancreatic sphincterotomy for sphincter of Oddi dysfunction? A conundrum for experts only. *Gastrointest Endosc* 2006; **64**: 723-725 [PMID: 17055864 DOI: 10.1016/j.gie.2006.04.018]

21 **Kim MH**, Myung SJ, Kim YS, Kim HJ, Seo DW, Nam SW, Ahn JH, Lee SK, Min YI. Routine biliary sphincterotomy may not be indispensable for endoscopic pancreatic sphincterotomy. *Endoscopy* 1998; **30**: 697-701 [PMID: 9865559 DOI: 10.1055/s-2007-1001391]

22 **Cotton PB**. Duodenoscopic papillotomy at the minor papilla for recurrent dorsal pancreatitis. Endosc Digest 1978; **3**: 27-28.

23 **Vitale GC**, Vitale M, Vitale DS, Binford JC, Hill B. Long-term follow-up of endoscopic stenting in patients with chronic pancreatitis secondary to pancreas divisum. *Surg Endosc* 2007; **21**: 2199-2202 [PMID: 17514389 DOI: 10.1007/s00464-007-9347-0]

24 **Watkins J L**, Lehman G A, Minor Papilla Endscopic Sphincterotomy. ERCP editors Baron T H, Kozarrek R, Carr-Lock D L, Elseiver 2008; 143-157.

25 **Lehman GA**, Sherman S, Nisi R, Hawes RH. Pancreas divisum: results of minor papilla sphincterotomy. *Gastrointest Endosc* 1993; **39**: 1-8 [PMID: 8454127 DOI: 10.1016/S0016-5107(93)70001-2]

26 **Attwell A**, Borak G, Hawes R, Cotton P, Romagnuolo J. Endoscopic pancreatic sphincterotomy for pancreas divisum by using a needle-knife or standard pull-type technique: safety and reintervention rates. *Gastrointest Endosc* 2006; **64**: 705-711 [PMID: 17055861 DOI: 10.1016/j.gie.2006.02.057]

27 **Delhaye M**, Matos C, Devière J. Endoscopic technique for the management of pancreatitis and its complications. *Best Pract Res Clin Gastroenterol* 2004; **18**: 155-181 [PMID: 15123090 DOI: 10.1016/S1521-6918(03)00077-5]

28 **Eleftherladis N**, Dinu F, Delhaye M, Le Moine O, Baize M, Vandermeeren A, Hookey L, Devière J. Long-term outcome after pancreatic stenting in severe chronic pancreatitis. *Endoscopy* 2005; **37**: 223-230 [PMID: 18556820 DOI: 10.1055/s-2005-860988]

29 **Costamagna G**, Bulajic M, Tringali A, Pandolfi M, Gabbrielli A, Spada C, Petruzziello L, Familiari P, Mutignani M. Multiple stenting of refractory pancreatic duct strictures in severe chronic pancreatitis: long-term results. *Endoscopy* 2006; **38**: 254-259 [PMID: 16528652 DOI: 10.1055/s-2005-921069]

30 **Adler DG**, Lichtenstein D, Baron TH, Davila R, Egan JV, Gan SL, Qureshi WA, Rajan E, Shen B, Zuckerman MJ, Lee KK, VanGuilder T, Fanelli RD. The role of endoscopy in patients with chronic pancreatitis. *Gastrointest Endosc* 2006; **63**: 933-937 [PMID: 16733106 DOI: 10.1016/j.gie.2006.02.003]

31 **Kozarek RA**. Pancreatic stents can induce ductal changes consistent with chronic pancreatitis. *Gastrointest Endosc* ; **36**: 93-95 [PMID: 2335298 DOI: 10.1016/S0016-5107(90)70958-3]

32 **Raju GS**, Gomez G, Xiao SY, Ahmed I, Brining D, Bhutani MS, Kalloo AN, Pasricha PJ. Effect of a novel pancreatic stent design on short-term pancreatic injury in a canine model. *Endoscopy* 2006; **38**: 260-265 [PMID: 16528653]

33 **Ishihara T**, Yamaguchi T, Seza K, Tadenuma H, Saisho H. Efficacy of s-type stents for the treatment of the main pancreatic duct stricture in patients with chronic pancreatitis. *Scand J Gastroenterol* 2006; **41**: 744-750 [PMID: 16716976 DOI: 10.1080/00365520500383597]

34 **Park do H**, Kim MH, Moon SH, Lee SS, Seo DW, Lee SK. Feasibility and safety of placement of a newly designed, fully covered self-expandable metal stent for refractory benign pancreatic ductal strictures: a pilot study (with video). *Gastrointest Endosc* 2008; **68**: 1182-1189 [PMID: 19028228 DOI: 10.1016/j.gie.2008.07.027]

35 **Moon SH**, Kim MH, Park do H, Song TJ, Eum J, Lee SS, Seo DW, Lee SK. Modified fully covered self-expandable metal stents with antimigration features for benign pancreatic-duct strictures in advanced chronic pancreatitis, with a focus on the safety profile and reducing migration. *Gastrointest Endosc* 2010; **72**: 86-91 [PMID: 20493483 DOI: 10.1016/j.gie.2010.01.063]

36 **Dumonceau JM**, Delhaye M, Tringali A, Dominguez-Munoz JE, Poley JW, Arvanitaki M, Costamagna G, Costea F, Devière J, Eisendrath P, Lakhtakia S, Reddy N, Fockens P, Ponchon T, Bruno M. Endoscopic treatment of chronic pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. *Endoscopy* 2012; **44**: 784-800 [PMID: 22752888 DOI: 10.1055/s-0032-1309840]

37 **Ong WC**, Tandan M, Reddy V, Rao GV, Reddy N. Multiple main pancreatic duct stones in tropical pancreatitis: safe clearance with extracorporeal shockwave lithotripsy. *J Gastroenterol Hepatol* 2006; **21**: 1514-1518 [PMID: 16928210 DOI: 10.1111/j.1440-1746.2006.04224.x]

38 **Chari S**, Jayanthi V, Mohan V, Malathi S, Madanagopalan N, Viswanathan M. Radiological appearance of pancreatic calculi in tropical versus alcoholic chronic pancreatitis. *J Gastroenterol Hepatol* 1992; **7**: 42-44 [PMID: 1543866 DOI: 10.1111/j.1440-1746.1992.tb00932.x]

39 **Lehman GA**. Role of ERCP and other endoscopic modalities in chronic pancreatitis. *Gastrointest Endosc* 2002; **56**: S237-S240 [PMID: 12447274 DOI: 10.1016/S0016-5107(02)70018-7]

40 **Sauerbruch T**, Holl J, Sackmann M, Paumgartner G. Extracorporeal lithotripsy of pancreatic stones in patients with chronic pancreatitis and pain: a prospective follow up study. *Gut* 1992; **33**: 969-972 [PMID: 1644340 DOI: 10.1136/gut.33.7.969]

41 **Delhaye M**, Vandermeeren A, Baize M, Cremer M. Extracorporeal shock-wave lithotripsy of pancreatic calculi. *Gastroenterology* 1992; **102**: 610-620 [PMID: 1732129]

42 **Dumonceau JM**, Devière J, Le Moine O, Delhaye M, Vandermeeren A, Baize M, Van Gansbeke D, Cremer M. Endoscopic pancreatic drainage in chronic pancreatitis associated with ductal stones: long-term results. *Gastrointest Endosc* 1996; **43**: 547-555 [PMID: 8781931 DOI: 10.1016/S0016-5107(96)70189-X]

43 **Costamagna G**, Gabbrielli A, Mutignani M, Perri V, Pandolfi M, Boscaini M, Crucitti F. Extracorporeal shock wave lithotripsy of pancreatic stones in chronic pancreatitis: immediate and medium-term results. *Gastrointest Endosc* 1997; **46**: 231-236 [PMID: 9378210 DOI: 10.1016/S0016-5107(97)70092-0]

44 **Neuhaus H**. Fragmentation of pancreatic stones by extracorporeal shock wave lithotripsy. *Endoscopy* 1991; **23**: 161-165 [PMID: 1860446 DOI: 10.1055/s-2007-1010647]

45 **Kozarek RA**, Brandabur JJ, Ball TJ, Gluck M, Patterson DJ, Attia F, France R, Traverso LW, Koslowski P, Gibbons RP. Clinical outcomes in patients who undergo extracorporeal shock wave lithotripsy for chronic calcific pancreatitis. *Gastrointest Endosc* 2002; **56**: 496-500 [PMID: 12297763 DOI: 10.1016/S0016-5107(02)70432-X]

46 **Guda NM**, Partington S, Freeman ML. Extracorporeal shock wave lithotripsy in the management of chronic calcific pancreatitis: a meta-analysis. *JOP* 2005; **6**: 6-12 [PMID: 15650279]

47 **Nguyen-Tang T**, Dumonceau JM. Endoscopic treatment in chronic pancreatitis, timing, duration and type of intervention. *Best Pract Res Clin Gastroenterol* 2010; **24**: 281-298 [PMID: 20510829 DOI: 10.1016/j.bpg.2010.03.002]

48 **Darisetty S**, Tandan M, Reddy DN, Kotla R, Gupta R, Ramchandani M, Lakhtakia S, Rao GV, Banerjee R. Epidural anesthesia is effective for extracorporeal shock wave lithotripsy of pancreatic and biliary calculi. *World J Gastrointest Surg* 2010; **2**: 165-168 [PMID: 21160867 DOI: 10.4240/wjgs.v2.i5.165]

49 **Tandan M**, Reddy DN. Extracorporeal shock wave lithotripsy for pancreatic and large common bile duct stones. *World J Gastroenterol* 2011; **17**: 4365-4371 [PMID: 22110261 DOI: 10.3748/wjg.v17.i39.4365]

50 **Ohara H**, Hoshino M, Hayakawa T, Kamiya Y, Miyaji M, Takeuchi T, Okayama Y, Gotoh K. Single application extracorporeal shock wave lithotripsy is the first choice for patients with pancreatic duct stones. *Am J Gastroenterol* 1996; **91**: 1388-1394 [PMID: 8678001]

51 **Dumonceau JM**, Costamagna G, Tringali A, Vahedi K, Delhaye M, Hittelet A, Spera G, Giostra E, Mutignani M, De Maertelaer V, Devière J. Treatment for painful calcified chronic pancreatitis: extracorporeal shock wave lithotripsy versus endoscopic treatment: a randomised controlled trial. *Gut* 2007; **56**: 545-552 [PMID: 17047101 DOI: 10.1136/gut.2006.096883]

52 **Delhaye M**, Arvanitakis M, Verset G, Cremer M, Devière J. Long-term clinical outcome after endoscopic pancreatic ductal drainage for patients with painful chronic pancreatitis. *Clin Gastroenterol Hepatol* 2004; **2**: 1096-1106 [PMID: 15625655 DOI: 10.1016/S1542-3565(04)00544-0]

53 **Seven G**, Schreiner MA, Ross AS, Lin OS, Gluck M, Gan SI, Irani S, Brandabur JJ, Patterson D, Kuhr C, Kozarek R. Long-term outcomes associated with pancreatic extracorporeal shock wave lithotripsy for chronic calcific pancreatitis. *Gastrointest Endosc* 2012; **75**: 997-1004.e1 [PMID: 22401819 DOI: 10.1016/j.gie.2012.01.014]

54 Long-term clinical outcomes of extracorporeal shockwave lithotripsy in painful chronic calcific pancreatitis. *Gastrointest Endosc* 2013; [PMID: 23891416]

55 **Hirai T**, Goto H, Hirooka Y, Itoh A, Hashimoto S, Niwa Y, Hayakawa T. Pilot study of pancreatoscopic lithotripsy using a 5-fr instrument: selected patients may benefit. *Endoscopy* 2004; **36**: 212-216 [PMID: 14986218 DOI: 10.1055/s-2004-814250]

56 **Howell DA**, Dy RM, Hanson BL, Nezhad SF, Broaddus SB. Endoscopic treatment of pancreatic duct stones using a 10F pancreatoscope and electrohydraulic lithotripsy. *Gastrointest Endosc* 1999; **50**: 829-833 [PMID: 10570346 DOI: 10.1016/S0016-5107(99)70168-9]

57 **Barthet M**, Bernard JP, Duval JL, Affriat C, Sahel J. Biliary stenting in benign biliary stenosis complicating chronic calcifying pancreatitis. *Endoscopy* 1994; **26**: 569-572 [PMID: 8001482 DOI: 10.1055/s-2007-1009041]

58 **Kahl S**, Zimmermann S, Genz I, Glasbrenner B, Pross M, Schulz HU, Mc Namara D, Schmidt U, Malfertheiner P. Risk factors for failure of endoscopic stenting of biliary strictures in chronic pancreatitis: a prospective follow-up study. *Am J Gastroenterol* 2003; **98**: 2448-2453 [PMID: 14638347 DOI: 10.1111/j.1572-0241.2003.08667.x]

59 **Catalano MF**, Linder JD, George S, Alcocer E, Geenen JE. Treatment of symptomatic distal common bile duct stenosis secondary to chronic pancreatitis: comparison of single vs. multiple simultaneous stents. *Gastrointest Endosc* 2004; **60**: 945-952 [PMID: 15605010 DOI: 10.1016/S0016-5107(04)02275-8]

60 **Cahen DL**, Rauws EA, Gouma DJ, Fockens P, Bruno MJ. Removable fully covered self-expandable metal stents in the treatment of common bile duct strictures due to chronic pancreatitis: a case series. *Endoscopy* 2008; **40**: 697-700 [PMID: 18704837 DOI: 10.1055/s-2008-1077353]

61 **Behm B**, Brock A, Clarke BW, Ellen K, Northup PG, Dumonceau JM, Kahaleh M. Partially covered self-expandable metallic stents for benign biliary strictures due to chronic pancreatitis. *Endoscopy* 2009; **41**: 547-551 [PMID: 19533560 DOI: 10.1055/s-0029-1214708]

62 **Deviere JM**, Reddy DN, Puspok A et al. Preliminary results from a 187 patient multicenter prospective trial using metal stents for treatemnt of benign biliary strictures. Gastrointest Endosc 2012: **75:** AB123. doi: 10.1016/j.gie.2012.04.018

63 **Telford JJ**, Farrell JJ, Saltzman JR, Shields SJ, Banks PA, Lichtenstein DR, Johannes RS, Kelsey PB, Carr-Locke DL. Pancreatic stent placement for duct disruption. *Gastrointest Endosc* 2002; **56**: 18-24 [PMID: 12085030 DOI: 10.1067/mge.2002.125107]

64 **Andrén-Sandberg A**, Dervenis C. Pancreatic pseudocysts in the 21st century. Part I: classification, pathophysiology, anatomic considerations and treatment. *JOP* 2004; **5**: 8-24 [PMID: 14730118]

65 **Lerch MM**, Stier A, Wahnschaffe U, Mayerle J. Pancreatic pseudocysts: observation, endoscopic drainage, or resection? *Dtsch Arztebl Int* 2009; **106**: 614-621 [PMID: 19890418]

66 **Andrén-Sandberg A**, Dervenis C. Pancreatic pseudocysts in the 21st century. Part II: natural history. *JOP* 2004; **5**: 64-70 [PMID: 15007187]

67 **Beckingham IJ**, Krige JE, Bornman PC, Terblanche J. Endoscopic management of pancreatic pseudocysts. *Br J Surg* 1997; **84**: 1638-1645 [PMID: 9448608 DOI: 10.1002/bjs.1800841204]

68 **Cahen D**, Rauws E, Fockens P, Weverling G, Huibregtse K, Bruno M. Endoscopic drainage of pancreatic pseudocysts: long-term outcome and procedural factors associated with safe and successful treatment. *Endoscopy* 2005; **37**: 977-983 [PMID: 16189770 DOI: 10.1055/s-2005-870336]

69 **Balachandra S**, Siriwardena AK. Systematic appraisal of the management of the major vascular complications of pancreatitis. *Am J Surg* 2005; **190**: 489-495 [PMID: 16105542 DOI: 10.1016/j.amjsurg.2005.03.009]

70 **Varadarajulu S**, Trevino J. Wilcox CM et al. Randomized trial comparing EUS and surgery for pancreatic pseudocyst drainage. Gastrointest Endosc 2010: **71**: AB116-AB116. doi: 10.1016/j.gie.2010.03.047

71 **Hookey LC**, Debroux S, Delhaye M, Arvanitakis M, Le Moine O, Devière J. Endoscopic drainage of pancreatic-fluid collections in 116 patients: a comparison of etiologies, drainage techniques, and outcomes. *Gastrointest Endosc* 2006; **63**: 635-643 [PMID: 16564865 DOI: 10.1016/j.gie.2005.06.028]

72 **Banerjee S**, Shen B, Baron TH, Nelson DB, Anderson MA, Cash BD, Dominitz JA, Gan SI, Harrison ME, Ikenberry SO, Jagannath SB, Lichtenstein D, Fanelli RD, Lee K, van Guilder T, Stewart LE. Antibiotic prophylaxis for GI endoscopy. *Gastrointest Endosc* 2008; **67**: 791-798 [PMID: 18374919 DOI: 10.1016/j.gie.2008.02.068]

73 **Sanchez Cortes E**, Maalak A, Le Moine O, Baize M, Delhaye M, Matos C, Devière J. Endoscopic cystenterostomy of nonbulging pancreatic fluid collections. *Gastrointest Endosc* 2002; **56**: 380-386 [PMID: 12196776 DOI: 10.1016/S0016-5107(02)70042-4]

74 **Kahaleh M**, Shami VM, Conaway MR, Tokar J, Rockoff T, De La Rue SA, de Lange E, Bassignani M, Gay S, Adams RB, Yeaton P. Endoscopic ultrasound drainage of pancreatic pseudocyst: a prospective comparison with conventional endoscopic drainage. *Endoscopy* 2006; **38**: 355-359 [PMID: 16680634 DOI: 10.1055/s-2006-925249]

75 Equal Efficacy of Endoscopic and Surgical Cystogastrostomy for Pancreatic Pseudocyst Drainage in a Randomized Trial. *Gastroenterology* 2013; [PMID: 23732774]

76 **Kahaleh M**, Hernandez AJ, Tokar J, Adams RB, Shami VM, Yeaton P. EUS-guided pancreaticogastrostomy: analysis of its efficacy to drain inaccessible pancreatic ducts. *Gastrointest Endosc* 2007; **65**: 224-230 [PMID: 17141775 DOI: 10.1016/j.gie.2006.05.008]

77 **Tessier G**, Bories E, Arvanitakis M, Hittelet A, Pesenti C, Le Moine O, Giovannini M, Devière J. EUS-guided pancreatogastrostomy and pancreatobulbostomy for the treatment of pain in patients with pancreatic ductal dilatation inaccessible for transpapillary endoscopic therapy. *Gastrointest Endosc* 2007; **65**: 233-241 [PMID: 17258981 DOI: 10.1016/j.gie.2006.06.029]

78 **Brauer BC**, Chen YK, Fukami N, Shah RJ. Single-operator EUS-guided cholangiopancreatography for difficult pancreaticobiliary access (with video). *Gastrointest Endosc* 2009; **70**: 471-479 [PMID: 19560768 DOI: 10.1016/j.gie.2008.12.233]

79 **Puli SR**, Reddy JB, Bechtold ML, Antillon MR, Brugge WR. EUS-guided celiac plexus neurolysis for pain due to chronic pancreatitis or pancreatic cancer pain: a meta-analysis and systematic review. *Dig Dis Sci* 2009; **54**: 2330-2337 [PMID: 19137428 DOI: 10.1007/s10620-008-0651-x]

80 **Kaufman M**, Singh G, Das S, Concha-Parra R, Erber J, Micames C, Gress F. Efficacy of endoscopic ultrasound-guided celiac plexus block and celiac plexus neurolysis for managing abdominal pain associated with chronic pancreatitis and pancreatic cancer. *J Clin Gastroenterol* 2010; **44**: 127-134 [PMID: 19826273 DOI: 10.1097/MCG.0b013e3181bb854d]

81 **Gress F**, Schmitt C, Sherman S, Ciaccia D, Ikenberry S, Lehman G. Endoscopic ultrasound-guided celiac plexus block for managing abdominal pain associated with chronic pancreatitis: a prospective single center experience. *Am J Gastroenterol* 2001; **96**: 409-416 [PMID: 11232683 DOI: 10.1111/j.1572-0241.2001.03551.x]

82 **Santosh D**, Lakhtakia S, Gupta R, Reddy DN, Rao GV, Tandan M, Ramchandani M, Guda NM. Clinical trial: a randomized trial comparing fluoroscopy guided percutaneous technique vs. endoscopic ultrasound guided technique of coeliac plexus block for treatment of pain in chronic pancreatitis. *Aliment Pharmacol Ther* 2009; **29**: 979-984 [PMID: 19222416 DOI: 10.1111/j.1365-2036.2009.03963.x]

**P-Reviewers** Kawa S, Yen HH  **S-Editor** Wen LL  **L-Editor**  **E-Editor**



**Figure 1 Large pancreatic calculi in head and genu in a patient of pancreas divisum with chronic pancreatitis cleared by extracorporeal shockwave lithotripsy followed by pancreatic stenting[49].**



**Figure 2 Large pancreatic calculi in head.** Post extracorporeal shockwave lithotripsy reduction in diameter of main pancreatic duct[49]**.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Pancreatic calculi with pain as the dominant symptom** | | | | | |
|  |  |  | |  |  |
| Imaging of pancreas (US / EUS / MRCP / ERCP) | | | | | |
|  |  |  | |  |  |
| Large pancreatic ductal calculi (Head & body) | | | | | |
|  |  | |  |  |  |
| Radio-opaque | | |  | Radio-lucent | |
|  |  | |  |  |  |
| ESWL–Fragmentation  (< 3 mm) | | |  | ERCP – EPS + NPT | |
|  |  | |  |  |  |
|  |  | |  | ESWL – Fragmentation  (< 3mm) | |
|  |  | |  |  |  |
| ERCP - EPS + | | |  | ERCP - | |
| PD Clearance +/- stent | | |  | PD Clearance +/- Stent | |

**Figure 3 Protocol followed for extracorporeal shockwave lithotripsy in Chronic calcific pancreatitis.** NPT: Naso pancreatic tube; EPS: Endoscopic pancreatic sphincterotomy; ERCP: Endoscopic retrograde cholangiopancreatography; ESWL: Extracorporeal shockwave lithotripsy; US: Ultrasonography; PD: Pancreatic duct.

**Figure 4 Mid body leak (arrow) with extravasated contrast in a patient with chronic pancreatitis and dilated pancreatic duct**. Stent placed across the leak.

